Murat Iskar

7PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSustainable architectureMicro- and nanosystemsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast

|Nov 02, 2024
Author Correction: Systematic assessment of ISWI subunits shows that NURF creates local accessibility for CTCF.

Mario Iurlaro, Francesca Masoni, Ilya M Flyamer

|May 30, 2024
Systematic assessment of ISWI subunits shows that NURF creates local accessibility for CTCF.

Mario Iurlaro, Francesca Masoni, Ilya M Flyamer

|Oct 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.

Sophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt

|Jul 30, 2017
Tumor-derived exosomes modulate PD-L1 expression in monocytes.

Franziska Haderk, Ralph Schulz, Murat Iskar

Pageof 2